Påt A. Holme

Author information from the last article

Department of Haematology

Oslo University Hospital

and

Institute of Clinical Medicine

University of Oslo

Author contribution: literature search, revision of the manuscript and approval of the submitted version

The author has completed the ICMJE form and declares the following conflict of interest: he has received speaker fees from Takeda (manufacturer of recombinant von Willebrand factor) regarding the treatment of von Willebrand disease.

Articles by Påt A. Holme

Von Willebrand disease

Ragnhild J. Måseide,
Erik Berntorp,
Geir E. Tjønnfjord,
Påt A. Holme

27.03.2026: Von Willebrand disease is the most common inherited bleeding disorder and is characterised by bleeding from the skin and mucous membranes. The severity of the disease can vary, and women are often more severely affected than men. Patients with von Willebrand disease can require multidisciplinary...